UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1262-7
Program Prior Authorization/Notification
Medication Vizimpro® (dacomitinib)
P&T Approval Date 11/2018, 11/2019, 11/2020, 11/2021, 11/2022, 11/2023, 11/2024
Effective Date 2/1/2025
1. Background:
Vizimpro® (dacomitinib) is a kinase inhibitor indicated for the first-line treatment of patients with
metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)
exon 19 deletion or exon 21 L858R substitution mutations. The National Cancer Comprehensive
Network (NCCN) also recommends the use of Vizimpro as first-line or continuation of therapy
for recurrent, advanced, or metastatic NSCLC with EGFR S768I, L861Q, and/or G719X mutation
positive tumors.
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Vizimpro will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Non-small cell lung cancer (NSCLC)
1. Initial Authorization
a. Vizimpro will be approved based on all of the following criteria:
(1) Diagnosis of NSCLC
-AND-
(2) Disease is recurrent, advanced or metastatic
-AND-
© 2024 UnitedHealthcare Services, Inc.
1
(3) Disease is positive for one of the following EGFR mutations:
(a) Exon 19 deletion
(b) Exon 21 L858R substitution
(c) S768I
(d) L861Q
(e) G719X
Authorization will be issued for 12 months.
2. Reauthorization
a. Vizimpro will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Vizimpro
therapy
Authorization will be issued for 12 months.
C. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Vizimpro [package insert]. Pfizer Labs: New York, NY; December 2020.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
http://www.nccn.org. Accessed September 25, 2024.
© 2024 UnitedHealthcare Services, Inc.
2
Program Prior Authorization/Notification – Vizimpro (dacomitinib)
Change Control
11/2018 New program.
11/2019 Annual review. Added NCCN recommended regimens criteria.
Updated references.
11/2020 Annual review. Updated coverage criteria based on NCCN
recommendations. Updated background and references.
11/2021 Annual review. Updated coverage criteria based on NCCN
recommendations. Updated background and references.
11/2022 Annual review. Added coverage for EGFR S768I, L861Q, and G719X
mutation positive tumors under coverage criteria for non-small cell lung
cancer per NCCN guidelines. Updated background, added state
mandate, and updated references.
11/2023 Annual review. Updated reference.
11/2024 Annual review. No changes to coverage criteria.
© 2024 UnitedHealthcare Services, Inc.
3